



**S2 Fig.** Progression-free survival and overall survival analysis. BR, bendamustine and rituximab; NR, not reached; OS, overall survival; PFS, progression-free survival; RCHOP, rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone; RCVP, cyclophosphamide, vincristine, and prednisolone.